# SLN catalysts: Silence Therapeutics plc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/sln/catalysts

> Silence Therapeutics plc (SLN) has 1 upcoming catalyst. The next is the divesiran trial start, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SLN?

Silence Therapeutics plc (SLN) has 1 upcoming catalyst. The next is the divesiran trial start, 1H 2027. SEC Form 8-K: "Based on the Phase 2 results, the Company expects to initiate a Phase 3 trial evaluating divesiran for Q12W dosing vs. placebo in the first half of 2027." [Calendar and source filings](https://sec-api.dev/companies/sln/catalysts)

Source: SEC Form 8-K, accession 0001193125-26-341293, https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/d12947d8k.htm (retrieved 2026-11-12). Last confirmed 2026-08-12. Cite: https://sec-api.dev/companies/sln/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Silence Therapeutics plc |
| Ticker | SLN (Nasdaq) |
| SEC CIK | 1479615 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/sln |

## Cash runway

Cash $247.7M as of 2026-09-30; quarterly burn $12.8M; about 58.2 months of runway at that rate (XBRL company facts, accession 0001193125-26-458896).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [Divesiran interim data readout](https://sec-api.dev/pdufa/divesiran) | SLN |  | completed, positive | "In June 2024, we reported positive interim results from the Phase 1 portion of the SANRECO trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000095017024126791/sln-ex99_1.htm)) |
| Dec 2024 | [Divesiran interim data readout](https://sec-api.dev/pdufa/divesiran) | SLN |  | completed, positive | "In December 2024, we presented positive interim results from the Phase 1 portion of the SANRECO Phase 1/2 clinical trial of divesiran in PV patients at the 66th American Society of Hematology (ASH) Annual Meeting." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1479615/000095017025029129/sln-20241231.htm)) |
| December 9, 2024 | [Divesiran trial start](https://sec-api.dev/pdufa/divesiran) | SLN |  | completed | "Silence also announces first subject dosed in Phase 2 study of divesiran in PV patients" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312524272929/d911238dex991.htm)) |
| February 27, 2025 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312525039248/d925669dex991.htm)) |
| May 8, 2025 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312525115533/d932196dex991.htm)) |
| August 7, 2025 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312525174958/d14149dex991.htm)) |
| November 6, 2025 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312525268102/sln-ex99_1.htm)) |
| March 5, 2026 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312526092578/sln-ex99_1.htm)) |
| May 7, 2026 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312526210428/sln-ex99_1.htm)) |
| Q3 2026 | [Silence Therapeutics plc interim data readout](https://sec-api.dev/companies/sln/catalysts) | SLN |  | scheduled | "The trial is fully enrolled and initial topline results are anticipated in the third quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1479615/000119312526092591/sln-20251231.htm)) |
| Q3 2026 | [Divesiran interim data readout](https://sec-api.dev/pdufa/divesiran) | SLN |  | scheduled | "Initial topline results from the SANRECO Phase 2 study are anticipated in the third quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312525247692/sln-ex99_1.htm)) |
| Q3 2026 | [Silence Therapeutics plc interim data readout](https://sec-api.dev/companies/sln/catalysts) | SLN |  | scheduled | "Following accelerated completion of Phase 2 enrollment, initial topline results from SANRECO are anticipated in the third quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1479615/000119312525268116/sln-20250930.htm)) |
| August 10, 2026 | [Divesiran topline data readout](https://sec-api.dev/pdufa/divesiran) | SLN |  | completed, positive | "On August 10, 2026, Silence reported positive topline results from its Phase 2 SANRECO trial of divesiran, an investigational siRNA therapy silencing TMPRSS6, in polycythemia vera, supporting a potentially best-in-class profile with once-every-three-month dosing." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312526457060/d101909dex991.htm)) |
| August 10, 2026 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312526341240/d162225dex991.htm)) |
| November 12, 2026 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312526457060/d101909dex991.htm)) |
| 1H 2027 | [Divesiran trial start](https://sec-api.dev/pdufa/divesiran) | SLN |  | scheduled | "Based on the Phase 2 results, the Company expects to initiate a Phase 3 trial evaluating divesiran for Q12W dosing vs. placebo in the first half of 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1479615/000119312526341293/d12947d8k.htm)) |

## Drugs

- [Divesiran](https://sec-api.dev/pdufa/divesiran): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/sln/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SLN catalysts: Silence Therapeutics plc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/sln/catalysts

```bibtex
@misc{secapidev_companies_sln_catalysts_20261116,
  title        = {SLN catalysts: Silence Therapeutics plc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/sln/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_sln_catalysts_20261116","title":"SLN catalysts: Silence Therapeutics plc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/sln/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
